$AXGN News
Last published 2d ago
- 2d agoAXGNAXOGEN: AVANCE PROSTATE UPDATE - AXOGEN INCEarnings Call TranscriptsGood morning, everyone, and welcome to AXIGEN's Prostate Nerve Reconstruction Investor Event. Joining me on today's call is Michael Dale, AXIGEN's President and Chief Executive Officer, Lindsay Hartley, Chief Financial O
- 1w agoAXGNAxogen, Inc. to Participate in Multiple Upcoming Investor ConferencesGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 2w agoAXGNAxogen, Inc. Reports 2026 Third Quarter Financial Results - AXOGEN INCEarnings Call TranscriptsGood morning, everyone. Joining me on today's call is Michael Dale, Axiogen's President and Chief Executive Officer, and Lindsay Hartley, Chief Financial Officer. Michael will discuss third quarter 2026 financial results
- 2w agoAXGNAxogen, Inc. - EX-99.1 Q3 2026 EARNINGS PRESS RELEASEEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 2w agoAXGNAxogen, Inc. Reports Third Quarter 2026 Financial ResultsGlobeNewswireALACHUA and TAMPA, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today
- 4w agoAXGNAxogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026GlobeNewswireALACHUA, Fla. and TAMPA, Fla., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 1mo agoCNXUSOLVVCELAXGN+1Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.GlobeNewswireRENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a
- 1mo agoRTXIARTTMQPECO+1Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the WeekPR NewswireStock Preachers News Commentary - Big technology names pulled the Nasdaq Composite to a weekly gain while the Dow Jones Industrial Average and...
- 2mo agoAXGNAXOGEN CONFERENCE CALL - AXOGEN INCEarnings Call TranscriptsGood morning, everyone, and welcome to the Axelgen Biocircuit Technologies Acquisition Conference Call. On today's call is Michael Dale, AxelGen's Chief Executive Officer, and Lindsay Hartley, AxelGens' Chief Financial O
- 2mo agoAXGNAxogen Announces Pricing of $208.7 Million Public Offering of Common StockGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. ("Axogen" or the "Company") (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for
- 2mo agoAXGNAxogen Enters into Definitive Agreement to Acquire BioCircuit TechnologiesGlobeNewswireAcquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen’s addressable market within its focus markets Axogen’s commercial infrastructure, surgeon
- 2mo agoAXGNAxogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare ConferenceGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 3mo agoCNXUVCELAXGNKRYS+1Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill ItGlobeNewswireRENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy
- 3mo agoAXGNAxogen, Inc. Reports 2026 Second Quarter Financial Results - AXOGEN INCEarnings Call TranscriptsGood morning, everyone. Joining me on today's call is Michael Dale, Accident's President and Chief Executive Officer, and Lindsay Hartley, Chief Financial Officer. Michael will discuss second quarter 2026 financial resul
- 3mo agoAXGNTrace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging TechnologyPR NewswireTrace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced it has received a strategic ...
- 3mo agoAXGNAxogen, Inc. Reports Second Quarter 2026 Financial ResultsGlobeNewswireALACHUA, Fla. and TAMPA, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 3mo agoSTIMAXGNNeuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management ChangesGlobeNewswireNir Naor appointed Chief Financial Officer effective July 23, 2026, bringing more than 20 years of finance and life sciences experienceCory Anderson promoted to Executive Vice President and General Manager, Greenbrook
- 3mo agoAXGNAxogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026GlobeNewswireALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 5mo agoAXGNCNXUDDDESTA+1The Newest Name on Nasdaq Wants to Help the Body Rebuild ItselfGlobeNewswireIssued on behalf of Conexeu Sciences Inc.A biotech debut out of Reno is betting that the next wave of medicine won't replace tissue — it'll grow it back.NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Energy Metal News News
- 6mo agoACRXANIKAXGNBEAT+6TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesGlobeNewswireMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a
- 6mo agoAXGNAxogen, Inc. to Participate in the 2026 Bank of America Global Healthcare ConferenceGlobeNewswireALACHUA, Fla. and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 6mo agoAXGNAxogen, Inc. Reports 2026 First Quarter Financial ResultsAXOGEN INCEarnings Call TranscriptsGood morning, everyone. Joining me on today's call is Michael Dale, Axelrod's President and Chief Executive Officer, Lindsay Hartley, Chief Financial Officer. Michael will discuss first quarter 2026 financial results and
- 6mo agoAXGNAxogen, Inc. Reports First Quarter 2026 Financial ResultsGlobeNewswireALACHUA, Fla. and TAMPA, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 6mo agoAXGNCVRXCVRx Announces Nomination of Michael Dale for Election to the Board of DirectorsGlobeNewswireMINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with
- 7mo agoAXGNAxogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026GlobeNewswireALACHUA, Fla. and TAMPA, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 8mo agoAXGNAxogen, Inc. Reports 2025 Fourth Quarter Financial ResultsAXOGEN INCEarnings Call TranscriptsGood morning, everyone. Joining me on today's call is Michael Dale, Axelgen's Chief Executive Officer and Director, and Lindsay Hartley, Chief Financial Officer. Michael will discuss fourth quarter and full year 2025 fin
- 8mo agoAXGNAxogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 8mo agoAXGNAxogen, Inc. to Participate in Multiple Upcoming Investor ConferencesGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 9mo agoAXGNAxogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026GlobeNewswireALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 9mo agoAXGNAxogen Announces Pricing of Upsized $124 Million Public Offering of Common StockGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 9mo agoAXGNAxogen Announces Proposed Public Offering of Common StockGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 10mo agoAXGNAxogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025GlobeNewswireALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 10mo agoAXGNAxogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare ConferenceGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 11mo agoAXGNAxogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)GlobeNewswireALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve
- 1y agoAXGNAxogen, Inc. to Participate in Multiple Upcoming Investor ConferencesGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 1y agoAXGNAxogen, Inc. Reports Third Quarter 2025 Financial ResultsGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 1y agoAXGNAxogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025GlobeNewswireALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 1y agoAXGNAxogen, Inc. to Participate in Multiple Upcoming Investor ConferencesGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 1y agoAXGNAxogen Provides Update on FDA Review Timeline for Avance Nerve GraftGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal
- 1y agoAXGNAxogen, Inc. (AXGN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoAXGNAxogen, Inc. Reports Second Quarter 2025 Financial ResultsGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 1y agoAXGNAxogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewswireALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 1y agoAXGNAxogen, Inc. to report 2025 second quarter financial results on August 5, 2025GlobeNewswireALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,
- 1y agoAXGNAxogen, Inc to Participate at Goldman Sachs Global Healthcare ConferenceGlobeNewswireALACHUA, Fla. and TAMPA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that
- 1y agoAXGNAxogen, Inc. Reports 2025 First Quarter Financial ResultsGlobeNewswireALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported
- 1y agoAXGNAxogen Announces Chief Financial Officer TransitionGlobeNewswireALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the
- 1y agoAXGNAxogen, Inc. to report 2025 first quarter financial results on May 8, 2025GlobeNewswireALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it
- 1y agoAXGNAxogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the
- 1y agoAXGNAxogen, Inc. To Host Analyst & Investor Day on March 4thGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, will hold its
- 1y agoAXGNAxogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial ResultsGlobeNewswireALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported